These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 27904955)

  • 1. Etirinotecan pegol administration is associated with lower incidences of neutropenia compared to irinotecan administration.
    Sy SK; Sweeney TD; Ji C; Hoch U; Eldon MA
    Cancer Chemother Pharmacol; 2017 Jan; 79(1):57-67. PubMed ID: 27904955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrated population pharmacokinetics of etirinotecan pegol and its four metabolites in cancer patients with solid tumors.
    Sy SKB; Chia YL; Gordi T; Hoch U; Eldon MA
    Cancer Chemother Pharmacol; 2018 May; 81(5):897-909. PubMed ID: 29564497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonclinical pharmacokinetics and activity of etirinotecan pegol (NKTR-102), a long-acting topoisomerase 1 inhibitor, in multiple cancer models.
    Hoch U; Staschen CM; Johnson RK; Eldon MA
    Cancer Chemother Pharmacol; 2014 Dec; 74(6):1125-37. PubMed ID: 25228368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Irinotecan pharmacokinetics].
    Chabot GG; Robert J; Lokiec F; Canal P
    Bull Cancer; 1998 Dec; Spec No():11-20. PubMed ID: 9932079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: a randomised phase 2 study.
    Awada A; Garcia AA; Chan S; Jerusalem GH; Coleman RE; Huizing MT; Mehdi A; O'Reilly SM; Hamm JT; Barrett-Lee PJ; Cocquyt V; Sideras K; Young DE; Zhao C; Chia YL; Hoch U; Hannah AL; Perez EA;
    Lancet Oncol; 2013 Nov; 14(12):1216-25. PubMed ID: 24095299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized study of etirinotecan pegol versus irinotecan as second-line treatment for metastatic colorectal cancer.
    Lenz HJ; Philip P; Saunders M; Kolevska T; Mukherjee K; Samuel L; Bondarde S; Dobbs T; Tagliaferri M; Hoch U; Hannah AL; Berkowitz M
    Cancer Chemother Pharmacol; 2017 Dec; 80(6):1161-1169. PubMed ID: 29043412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro cytotoxicity, pharmacokinetics and tissue distribution in rats of MXN-004, a novel conjugate of polyethylene glycol and SN38.
    Zhou S; Li N; Wang X; Li C; Tian F; Ren S; Zhang Y; He Y; Qiu Z; Zhao D; Chen X
    Xenobiotica; 2014 Jun; 44(6):562-9. PubMed ID: 24308437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NKTR-102 Efficacy versus irinotecan in a mouse model of brain metastases of breast cancer.
    Adkins CE; Nounou MI; Hye T; Mohammad AS; Terrell-Hall T; Mohan NK; Eldon MA; Hoch U; Lockman PR
    BMC Cancer; 2015 Oct; 15():685. PubMed ID: 26463521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Etirinotecan pegol for the treatment of breast cancer.
    López-Miranda E; Cortés J
    Expert Opin Pharmacother; 2016; 17(5):727-34. PubMed ID: 26881332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I dose-escalation study of EZN-2208 (PEG-SN38), a novel conjugate of poly(ethylene) glycol and SN38, administered weekly in patients with advanced cancer.
    Patnaik A; Papadopoulos KP; Tolcher AW; Beeram M; Urien S; Schaaf LJ; Tahiri S; Bekaii-Saab T; Lokiec FM; Rezaï K; Buchbinder A
    Cancer Chemother Pharmacol; 2013 Jun; 71(6):1499-506. PubMed ID: 23543270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A multicenter, phase I, dose-escalation study to assess the safety, tolerability, and pharmacokinetics of etirinotecan pegol in patients with refractory solid tumors.
    Jameson GS; Hamm JT; Weiss GJ; Alemany C; Anthony S; Basche M; Ramanathan RK; Borad MJ; Tibes R; Cohn A; Hinshaw I; Jotte R; Rosen LS; Hoch U; Eldon MA; Medve R; Schroeder K; White E; Von Hoff DD
    Clin Cancer Res; 2013 Jan; 19(1):268-78. PubMed ID: 23136196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I study and pharmacokinetics of irinotecan (CPT-11) and paclitaxel in patients with advanced non-small cell lung cancer.
    Hotta K; Ueoka H; Kiura K; Tabata M; Kuyama S; Satoh K; Kozuki T; Hisamoto A; Hosokawa S; Fujiwara K; Tanimoto M
    Lung Cancer; 2004 Jul; 45(1):77-84. PubMed ID: 15196737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I and pharmacokinetic study of intravenous irinotecan plus oral ciclosporin in patients with fuorouracil-refractory metastatic colon cancer.
    Chester JD; Joel SP; Cheeseman SL; Hall GD; Braun MS; Perry J; Davis T; Button CJ; Seymour MT
    J Clin Oncol; 2003 Mar; 21(6):1125-32. PubMed ID: 12637480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase 1 and pharmacokinetic study of intravenous irinotecan in refractory solid tumor patients with hepatic dysfunction.
    Schaaf LJ; Hammond LA; Tipping SJ; Goldberg RM; Goel R; Kuhn JG; Miller LL; Compton LD; Cisar LA; Elfring GL; Gruia G; McGovren JP; Pirotta N; Yin D; Sharma A; Duncan BA; Rothenberg ML
    Clin Cancer Res; 2006 Jun; 12(12):3782-91. PubMed ID: 16778106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preparation, Pharmacokinetic Profile, and Tissue Distribution Studies of a Liposome-Based Formulation of SN-38 Using an UPLC-MS/MS Method.
    Li K; Wang S
    AAPS PharmSciTech; 2016 Dec; 17(6):1450-1456. PubMed ID: 26831446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I clinical and pharmacokinetic study of irinotecan in adults with recurrent malignant glioma.
    Gilbert MR; Supko JG; Batchelor T; Lesser G; Fisher JD; Piantadosi S; Grossman S
    Clin Cancer Res; 2003 Aug; 9(8):2940-9. PubMed ID: 12912940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Etirinotecan pegol in women with recurrent platinum-resistant or refractory ovarian cancer.
    Bardhi E; Marchetti C; Scopelliti A; Musacchio L; Tomao F; Schiavi M; Carraro C; Palaia I; Monti M; Muzii L; Benedetti Panici P
    Expert Opin Investig Drugs; 2019 Aug; 28(8):667-673. PubMed ID: 31353973
    [No Abstract]   [Full Text] [Related]  

  • 18. Novel prodrugs of SN38 using multiarm poly(ethylene glycol) linkers.
    Zhao H; Rubio B; Sapra P; Wu D; Reddy P; Sai P; Martinez A; Gao Y; Lozanguiez Y; Longley C; Greenberger LM; Horak ID
    Bioconjug Chem; 2008 Apr; 19(4):849-59. PubMed ID: 18370417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study.
    Chabot GG; Armand JP; Terret C; de Forni M; Abigerges D; Winograd B; Igwemezie L; Schacter L; Kaul S; Ropers J; Bonnay M
    J Clin Oncol; 1996 Jul; 14(7):2020-30. PubMed ID: 8683232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DTS-108, a novel peptidic prodrug of SN38: in vivo efficacy and toxicokinetic studies.
    Meyer-Losic F; Nicolazzi C; Quinonero J; Ribes F; Michel M; Dubois V; de Coupade C; Boukaissi M; Chéné AS; Tranchant I; Arranz V; Zoubaa I; Fruchart JS; Ravel D; Kearsey J
    Clin Cancer Res; 2008 Apr; 14(7):2145-53. PubMed ID: 18381956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.